COL4A gene variants are common in children with hematuria and a family history of kidney disease.
Alport syndrome
Focal segmental glomerulosclerosis
Genetic testing
Hematuria
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
20
12
2022
accepted:
15
04
2023
revised:
24
03
2023
medline:
22
9
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Inherited kidney diseases are a common cause of chronic kidney disease (CKD) in children. Identification of a monogenic cause of CKD is more common in children than in adults. This study evaluated the diagnostic yield and phenotypic spectrum of children who received genetic testing through the KIDNEYCODE sponsored genetic testing program. Unrelated children < 18 years of age who received panel testing through the KIDNEYCODE sponsored genetic testing program from September 2019 through August 2021 were included (N = 832). Eligible children met at least one of the following clinician-reported criteria: estimated GFR ≤ 90 ml/min/1.73 m A positive genetic diagnosis was observed in 234 children (28.1%, 95% CI [25.2-31.4%]) in genes associated with Alport syndrome (N = 213), FSGS (N = 9), or other disorders (N = 12). Among children with a family history of kidney disease, 30.8% had a positive genetic diagnosis. Among those with hematuria and a family history of CKD, the genetic diagnostic rate increased to 40.4%. Children with hematuria and a family history of CKD have a high likelihood of being diagnosed with a monogenic cause of kidney disease, identified through KIDNEYCODE panel testing, particularly COL4A variants. Early genetic diagnosis can be valuable in targeting appropriate therapy and identification of other at-risk family members. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
Inherited kidney diseases are a common cause of chronic kidney disease (CKD) in children. Identification of a monogenic cause of CKD is more common in children than in adults. This study evaluated the diagnostic yield and phenotypic spectrum of children who received genetic testing through the KIDNEYCODE sponsored genetic testing program.
METHODS
Unrelated children < 18 years of age who received panel testing through the KIDNEYCODE sponsored genetic testing program from September 2019 through August 2021 were included (N = 832). Eligible children met at least one of the following clinician-reported criteria: estimated GFR ≤ 90 ml/min/1.73 m
RESULTS
A positive genetic diagnosis was observed in 234 children (28.1%, 95% CI [25.2-31.4%]) in genes associated with Alport syndrome (N = 213), FSGS (N = 9), or other disorders (N = 12). Among children with a family history of kidney disease, 30.8% had a positive genetic diagnosis. Among those with hematuria and a family history of CKD, the genetic diagnostic rate increased to 40.4%.
CONCLUSIONS
Children with hematuria and a family history of CKD have a high likelihood of being diagnosed with a monogenic cause of kidney disease, identified through KIDNEYCODE panel testing, particularly COL4A variants. Early genetic diagnosis can be valuable in targeting appropriate therapy and identification of other at-risk family members. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 37204491
doi: 10.1007/s00467-023-05993-z
pii: 10.1007/s00467-023-05993-z
doi:
Substances chimiques
Collagen Type IV
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3625-3633Informations de copyright
© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
KDIGO Conference Participants (2022) Genetics in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 101:1126–1141. https://doi.org/10.1016/j.kint.2022.03.019
doi: 10.1016/j.kint.2022.03.019
pmcid: 9922534
Bullich G, Domingo-Gallego A, Vargas I et al (2018) A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. Kidney Int 94:363–371. https://doi.org/10.1016/j.kint.2018.02.027
doi: 10.1016/j.kint.2018.02.027
pubmed: 29801666
Mrug M, Bloom MS, Seto C et al (2021) Genetic testing for chronic kidney diseases: clinical utility and barriers perceived by Nephrologists. Kidney Med 3:1050–1056. https://doi.org/10.1016/j.xkme.2021.08.006
doi: 10.1016/j.xkme.2021.08.006
pubmed: 34939014
pmcid: 8664736
Vehaskari VM, Rapola J, Koskimies O, Savilahti E, Vilska J, Hallman N (1979) Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation. J Pediatr 95:676–684. https://doi.org/10.1016/s0022-3476(79)80710-6
doi: 10.1016/s0022-3476(79)80710-6
pubmed: 490233
Lieberman K, Chang A, Block G et al (2022) The KIDNEYCODE program: diagnostic yield and clinical features of individuals with chronic kidney disease. Kidney360 3:900–909. https://doi.org/10.34067/KID.0004162021
Groopman EE, Marasa M, Cameron-Christie S et al (2019) Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 380:142–151. https://doi.org/10.1056/NEJMoa1806891
doi: 10.1056/NEJMoa1806891
pubmed: 30586318
Kashtan CE, Ding J, Garosi G et al (2018) Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93:1045–1051. https://doi.org/10.1016/j.kint.2017.12.018
doi: 10.1016/j.kint.2017.12.018
pubmed: 29551517
Jais JP, Knebelmann B, Giatras I et al (2000) X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649–657. https://doi.org/10.1681/ASN.V114649
doi: 10.1681/ASN.V114649
pubmed: 10752524
Oka M, Nozu K, Kaito H et al (2014) Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 29:1535–1544
doi: 10.1007/s00467-014-2797-4
pubmed: 24633401
Furlano M, Martinez V, Pybus M et al (2021) Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study. Am J Kidney Dis 78:560-570.e1. https://doi.org/10.1007/s00467-014-2797-4
doi: 10.1007/s00467-014-2797-4
pubmed: 33838161
Savige J, Colville D, Rheault M et al (2016) Alport syndrome in women and girls. Clin J Am Soc Nephrol 11:1713–1720. https://doi.org/10.2215/CJN.00580116
doi: 10.2215/CJN.00580116
pubmed: 27287265
pmcid: 5012472
Gast C, Pengelly RJ, Lyon M et al (2016) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31:961–970. https://doi.org/10.1093/ndt/gfv325
doi: 10.1093/ndt/gfv325
pubmed: 26346198
Malone AF, Phelan PJ, Hall G et al (2014) Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 86:1253–1259. https://doi.org/10.1038/ki.2014.305
doi: 10.1038/ki.2014.305
pubmed: 25229338
pmcid: 4245465
Pierides A, Voskarides K, Athanasiou Y et al (2009) Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/ COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis. Nephrol Dial Transplant 24:2721–2729. https://doi.org/10.1093/ndt/gfp158
doi: 10.1093/ndt/gfp158
pubmed: 19357112
Gross O, Licht C, Anders HJ et al (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494–501. https://doi.org/10.1038/ki.2011.407
doi: 10.1038/ki.2011.407
pubmed: 22166847
Yamamura T, Horinouchi T, Nagano C et al (2020) Genotype-phenotype correlation and the influence of the genotype on response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 98:1605–1614. https://doi.org/10.1016/j.kint.2020.06.038
doi: 10.1016/j.kint.2020.06.038
pubmed: 32712167
Zhang Y, Bockhaus J, Wang F et al (2021) Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol 36:2719–2730. https://doi.org/10.1007/s00467-021-05040-9
doi: 10.1007/s00467-021-05040-9
pubmed: 33772369
pmcid: 8370956
Gross O, Tönshoff B, Weber LT et al (2020) A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 97:1275–1286. https://doi.org/10.1016/j.kint.2019.12.015
doi: 10.1016/j.kint.2019.12.015
pubmed: 32299679
Kashtan CE, Gross O (2021) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol 36:711–719. https://doi.org/10.1007/s00467-020-04819-6
doi: 10.1007/s00467-020-04819-6
pubmed: 33159213
Connaughton DM, Hildebrandt F (2020) Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant 35:390–397. https://doi.org/10.1093/ndt/gfz028
doi: 10.1093/ndt/gfz028
pubmed: 30809662
Connaughton DM, Kennedy C, Shril S et al (2019) Monogenic causes of chronic kidney disease in adults. Kidney Int 95:914–928. https://doi.org/10.1016/j.kint.2018.10.031
doi: 10.1016/j.kint.2018.10.031
pubmed: 30773290
pmcid: 6431580
Ottlewski I, Münch J, Wagner T et al (2019) Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease. Kidney Int 96:222–230. https://doi.org/10.1016/j.kint.2019.01.038
doi: 10.1016/j.kint.2019.01.038
pubmed: 31027891
Lata S, Marasa M, Li Y et al (2018) Whole-exome sequencing in adults with chronic kidney disease: a pilot study. Ann Intern Med 168:100–109. https://doi.org/10.7326/M17-1319
doi: 10.7326/M17-1319
pubmed: 29204651
Jayasinghe K, Stark Z, Kerr PG et al (2021) Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genet Med 23:183–191. https://doi.org/10.1038/s41436-020-00963-4
doi: 10.1038/s41436-020-00963-4
pubmed: 32939031
Morinière V, Dahan K, Hilbert P et al (2014) Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 25:2740–2751. https://doi.org/10.1681/ASN.2013080912
doi: 10.1681/ASN.2013080912
pubmed: 24854265
pmcid: 4243343
Cirillo L, Becherucci F (2022) Genetic testing in nephrology: show your pedigree! Kidney360 3:2148–2152. https://doi.org/10.34067/KID.0002732022
doi: 10.34067/KID.0002732022
pubmed: 36591360
pmcid: 9802562